PHARMENGAGE

Impact of Managed Therapy on Adherence to Medications Used to Treat Multiple Sclerosis and Related Comorbid Conditions

Results: Mean proportion of days covered rates improved significantly in the group managed for at least 6 months compared with those who were less managed. Positive screenings for fatigue and depression reduced adherence in the less-managed group but not in patients with longer participation in the program.

Conclusions: Overall, the CCMS program significantly increased adherence to MS medications. This improved adherence was not negatively impacted by positive screenings for fatigue and depression.

Article Citation: Janeen DuChane, Bobby Clark, Francis Staskon, Rick Miller, Kathleen Love, and Ian Duncan (2015) Walgreens Connected Care. International Journal of MS Care: March/April 2015, Vol. 17, No. 2, pp. 57-64.

To read more http://www.pharmengage.com/wp-content/uploads/2015/05/Impact-of-managed-therapy-on-adherence-Wallgreens.pdf

3 comments to “Impact of Managed Therapy on Adherence to Medications Used to Treat Multiple Sclerosis and Related Comorbid Conditions”

You can leave a reply or Trackback this post.
  1. Adherence to MS medications was measured as the proportion of days covered, with propensity scores used to match the CCMS intervention group to the less-managed comparison group. The impact of program participation on the relationship between depression or fatigue and adherence over time was a separate analysis.

  2. This improved adherence was not negatively impacted by positive screenings for fatigue and depression.

  3. I pay a visit every day a few web pages and websites to
    read posts, but this website offers feature based
    posts.

Write a Reply or Comment

Your email address will not be published.

TOP